Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	0.89	2.33	18.74
Revenue Growth (YoY)	-	-	-61.96%	-87.57%	-
Cost of Revenue	171.65	162.79	84.05	58.58	57.07
Gross Profit	-171.65	-162.79	-83.16	-56.25	-38.33
Selling, General & Admin	47.91	45.78	34.45	28.53	27.32
Operating Expenses	47.91	45.78	34.45	28.53	27.32
Operating Income	-219.56	-208.57	-117.61	-84.78	-65.65
Interest & Investment Income	24.89	21.31	6.15	0.84	0.11
Other Non Operating Income (Expenses)	29.46	-20.71	-102.66	-0.01	-0.12
EBT Excluding Unusual Items	-165.22	-207.97	-214.13	-83.95	-65.66
Merger & Restructuring Charges	-	-	-10.95	-	-
Gain (Loss) on Sale of Assets	10	-	16.45	-	-
Pretax Income	-155.22	-207.97	-338.82	-83.95	-65.66
Income Tax Expense	-0.02	0.05	-0.03	-0.14	0.14
Net Income	-155.2	-208.02	-338.79	-83.82	-65.8
Preferred Dividends & Other Adjustments	-28.66	-58.46	-243.91	-	-
Net Income to Common	-126.54	-149.56	-94.88	-83.82	-65.8
Shares Outstanding (Basic)	64	47	7	3	3
Shares Outstanding (Diluted)	64	47	7	3	3
Shares Change (YoY)	36.21%	581.85%	104.59%	28.19%	23.18%
EPS (Basic)	-1.98	-3.18	-13.76	-24.86	-25.02
EPS (Diluted)	-1.98	-3.18	-13.76	-24.86	-25.02
Free Cash Flow	-169.25	-157.41	-99.91	-80.18	-54.29
Free Cash Flow Per Share	-2.64	-3.35	-14.49	-23.78	-20.64
Gross Margin	-	-	-	-	-204.55%
Operating Margin	-	-	-13274.49%	-3640.23%	-350.33%
Profit Margin	-	-	-10709.14%	-3598.76%	-351.14%
Free Cash Flow Margin	-	-	-11276.52%	-3442.76%	-289.71%
EBITDA	-	-207.82	-116.87	-83.21	-64.07
D&A For EBITDA	-	0.74	0.74	1.57	1.58
EBIT	-219.56	-208.57	-117.61	-84.78	-65.65
Revenue as Reported	-	-	0.89	2.33	18.74

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q